

ONE 8/29/02

P.O. Box 806
Pelham, N.Y. 10803
Telephone: (914) 712-0093
Fax: (914) 712-0094/5

**Cheryl H. Agris, Ph.D.
Attorney at Law**

Fax

To: Examiner J. Roark From: Cheryl Agris
Fax: 1-703-746-5174 Pages: 9
Phone: 1-703-605-1209 Date: 8/29/02
Re: 09/559,764 (5694.200) CC:

☐ Urgent☒ For Review☐ Please Comment ☐ Please Reply

• Comments:

NOTICE OF CONFIDENTIALITY

The information contained in and transmitted with this facsimile is subject to the attorney-client privilege, attorney work product, or is confidential and is intended only for the individual or entity designated above. You are hereby notified that any dissemination, distribution, copying, or use of or reliance upon the information contained in and transmitted with this facsimile by or to anyone other than the recipient designated above by the sender is **unauthorized and strictly prohibited**. If you have received this facsimile in error or did not receive all pages, please notify Cheryl H. Agris, Ph.D. Attorney at Law at (914) 712-0093 immediately.

5694.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Flodgaard et al.

Serial No.: 09/559,764

Group Art Unit: 1644

Filed: April 27, 2000

Examiner: J. Roark

For: INHIBITION OF BRADYKININ RELEASE

Confirmation No.: 2707

CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:


1. Supplemental Response
2. Declaration Under 37 C.F.R. 1.132

was sent to the United States Patent and Trademark Office by telefax to the attention of
Examiner Jessica H. Roark, fax number (703) 746-5174.

Respectfully submitted,

Date:

8/29/02



Cheryl H. Agris, Reg. No. 34,086

Outside Counsel for

Novo Nordisk of North America, Inc.

405 Lexington Avenue, Suite 6400

New York, N.Y. 10017

Attorney Docket No.: 5694.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Flodgaard et al.

Application No.: 09/559,764

Group Art Unit: 1644

Filed: April 27, 2000

Examiner: J. Roark

For: Inhibition Of Bradykinin Release

SUPPLEMENTAL RESPONSE

Commissioner for Patents
Washington, DC 20231


Sir:

Further to Applicants' response filed on June 20, 2002, Applicants herewith submit a Declaration by Dr. Thomas Renne. As stated in the response, Dr. Renne presents results indicating that HBP displaces H-kininogen assembled on the surface of immobilized heparan sulfate or endothelial cells better than histidine-rich glycoprotein, factor XII or HK itself and that HBP and kininogen do directly interact.

The Examiner is hereby invited to contact the undersigned by telephone at (914) 712-0093 if there are any questions concerning this response.

Respectfully submitted,

Date: 8/29/02


Cheryl H. Agis, Reg. No. 34,086
Counsel for

Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6201